Ara 290 Peptide

ARA 290 peptide, also known as ARA-290 or Cibinetide, is an 11-amino acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR), a complex of the EPO receptor and β-common receptor. This activation promotes tissue protection, modulates the innate immune response, and shifts pro-inflammatory environments toward healing without stimulating erythropoiesis. By targeting IRR on endothelial cells, glia, and immune cells, the ARA 290 peptide enhances anti-inflammatory pathways, reduces neuropathic symptoms, and supports repair in conditions like small fiber neuropathy and neuropathic pain.

Clinical trials have demonstrated ARA 290’s efficacy in improving corneal nerve fiber density—a key marker of small fiber regeneration—in patients with sarcoidosis-associated small fiber neuropathy, alongside reductions in neuropathic pain and better quality-of-life scores. Preclinical studies in diabetic mouse sympathetic ganglia show ARA 290 reverses nerve degeneration, promotes tissue protection, and reprograms inflammation for repair. These findings highlight its potential as a disease-modifying therapy for neuropathic conditions, with Phase II trials confirming safety and structural nerve regrowth.

Buy Ara-290 For Research at Peptides Please

Ara-290, available for research purposes at Peptides Please, is a peptide derived from erythropoietin that mediates tissue protection by modulating the primary injury response, offering potential benefits in reversing experimental diabetic neuropathy as measured by the neuropathic pain symptom inventory. Researchers have explored its efficacy in sarcoidosis patients with painful neuropathy, where it supports tissue injury recovery while considering factors like body mass index, making it a promising compound for studies on neuropathy and related inflammatory conditions.

What Are Ara 290 Peptides

ARA-290 (Cibinetide) is a synthetic 11-amino acid peptide derived fromerythropoietin (EPO) that provides tissue-protective, anti-inflammatory, and nerve-repairing benefits without stimulating red blood cell production, as erythropoietin mediates tissue protection through innate repair receptor activation. By acting specifically on theinnate repair receptor (IRR), it inhibits macrophage activation, offering therapeutic potential for conditions like diabetic peripheral neuropathy and neuropathic pain.

Ara 290 Peptide Benefits

ARA-290, also known as Cibinetide, is a non-erythropoietic peptide that mimics erythropoietin’s (EPO) tissue-protective effects without boosting red blood cell production. It specifically targets the Innate Repair Receptor (IRR) to combat chronic neuropathic pain, inflammation, fibrotic damage, and metabolic dysfunction—making it promising for conditions like diabetic neuropathy and sarcoidosis.

• Neuropathic Pain Relief: Effectively reduces pain from diabetic neuropathy and sarcoidosis by modulating the innate immune system and inhibiting theTRPV1 pain receptor.
• Tissue Protection and Repair: Enhances regeneration, curbs injury-related inflammation, and promotes beneficialmicroglia polarization (M1 to M2 shift).
• Improved Diabetic Markers: Lowers HbA1c levels and improves lipid profiles in type 2 diabetes patients.
• Nerve Regeneration: Boosts corneal nerve fiber density, as shown in clinical trials.
• Reduced Inflammation and Fibrosis: Counters inflammation-driven tissue damage, with potential applications in autoimmune diseases and age-related cardiac inflammation.
• Superior Safety Profile: Avoids EPO’s risks like hypertension and clotting (no hematopoiesis induction); trials confirm safety even at high doses.

Ara-290 Mechanism of Action

ARA-290 (Cibinetide) is an 11-amino acid peptide that selectively activates the Innate Repair Receptor (IRR)—a heteromer of the erythropoietin (EPO) receptor and common receptor (ββCR)—without promoting red blood cell production. This triggers tissue-protective, anti-inflammatory, and neuroprotective pathways, especially during injury.

• IRR Activation: Binds the ββCR-EPO receptor complex, upregulated in damaged tissues, to initiate repair signaling.
• Anti-Inflammatory and Immunomodulatory Effects: Suppresses mediators likeTNF-α, reduces spinal microglial activation, and alleviates neuropathic pain and inflammation.
• Tissue Repair and Neuroprotection: Drives nerve fiber regeneration (neurite outgrowth), blocks apoptosis, and boosts cellular resilience.
• TRPV1 Antagonism: Directly inhibits the TRPV1 channel to decrease mechanical hypersensitivity beyond IRR effects.
• Metabolic Improvements: Enhances glucose-induced insulin release and glucose tolerance in diabetic neuropathy models.

Research Ara-290 Peptide for Sale at PeptidesPlease

Unlock the cutting-edge potential of Ara-290 peptide, a synthetic erythropoietin derivative revolutionizing research into neuropathic pain relief, tissue regeneration, and anti-aging protocols—at PeptidesPlease, your premier source for ultra-pure, lab-grade Ara-290 for sale. Renowned for its ability to activate the innate repair receptor without triggering unwanted blood cell growth, Ara-290 shows promising preclinical results in accelerating wound healing, reducing inflammation, and enhancing metabolic health, making it a must-have for biomedical researchers exploring bodybuilding recovery, weight loss synergies, and skincare innovations. With our 99%+ purity guarantee, rigorous third-party testing, and lightning-fast worldwide shipping from secure facilities, PeptidesPlease delivers research-grade Ara-290 at unbeatable prices—stock up today and elevate your peptide studies to new heights.

Frequently Asked Questions

What is Ara 290 used for?

ARA-290, also known as Cibinetide, is primarily researched for treating neuropathic pain conditions like sarcoidosis-associated small fiber neuropathy, diabetic neuropathy, and chemotherapy-induced peripheral neuropathy. It also shows potential in reducing inflammation, supporting nerve repair, and protecting organs such as the kidneys and heart in preclinical and clinical studies.

Is the ARA 290 FDA approved?

No, ARA-290 is not FDA approved for commercial therapeutic use; it remains an investigational drug in clinical development, with Phase II trials completed but Phase III needed.

What is another name for Ara 290?

ARA-290 is also known as Cibinetide.

Is Ara 290 legal?

ARA-290 is not legal for general sale or use outside clinical trials in the US, as it lacks FDA approval and is classified for research purposes only. Importing or purchasing it for personal use may result in seizure by authorities.

Summary

In summary, ARA-290 (also known as ARA 290) stands out as a promising non-erythropoietic peptide derived from erythropoietin, selectively targeting the innate repair receptor to deliver tissue-protective benefits without the hematopoietic side effects of its parent molecule. Extensive preclinical and early clinical research highlights its efficacy in mitigating neuropathic pain, reducing inflammation, promoting nerve repair, and improving symptoms in conditions like diabetic neuropathy, sarcoidosis, Parkinson’s disease, and traumatic brain injury, while also supporting metabolic control and cognitive function. With a strong safety profile demonstrated in human trials, ARA-290 holds substantial therapeutic potential as a disease-modifying agent for neurology and metabolic disorders, warranting further large-scale studies to fully unlock its clinical applications.